摘要
目的:分析慢性阻塞性肺疾病急性加重期(AECOPD)合并支气管扩张患者痰培养病原菌分布及耐药性。方法:收集2019年1月-2020年8月本院60例痰培养阳性的AECOPD合并支气管扩张患者的临床资料,分析痰培养病原菌的分布及其耐药性情况。结果:共检测出病原菌83株,21.69%为革兰阳性菌,61.45%为革兰阴性菌,16.87%为真菌。革兰阳性菌中,金黄色葡萄球菌占9.64%,肺炎链球菌占8.43%;革兰阴性菌中,铜绿假单胞菌占28.92%,肺炎克雷伯菌占13.25%,大肠埃希菌占9.64%;真菌中,白色念珠菌占12.05%。金黄色葡萄球菌对氨苄青霉素的耐药率为100%;肺炎链球菌对左氧氟沙星、万古霉素的耐药率均为0。铜绿假单胞菌对头孢曲松、氨曲南的耐药率均为41.67%;肺炎克雷伯菌对青霉素类的耐药率为54.55%,头孢曲松为45.45%,大肠埃希菌对青霉素类、头孢类的耐药率较高,达100%。白色念珠菌的两性霉素B的耐药率为10.00%,氟康唑为50.00%。结论:AECOPD合并支气管扩张患者常由革兰阴性菌感染,且对头孢类、青霉素类抗菌药耐药性较高,耐药性较为普遍,临床用药时还需合理使用各类抗菌药。
Objective:To analyze the distribution and drug resistance of pathogens in sputum culture of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and bronchiectasis.Method:The clinical data of 60 patients with AECOPD complicated with bronchiectasis with positive sputum culture in our hospital from January 2019 to August 2020 were collected to analyze the distribution and drug resistance of pathogens in sputum culture.Result:There were 83 strains of pathogens detected out,including Gram-positive bacteria(21.69%),Gram-negative bacteria(61.45%)and fungi(16.87%).Among Gram-positive bacteria,Staphylococcus aureus and Streptococcus pneumoniae accounted for 9.64%and 8.43%,respectively.Among Gram-negative bacteria,Pseudomonas aeruginosa,Klebsiella pneumoniae and Escherichia coli accounted for 28.92%,13.25%and 9.64%,respectively.Among fungi,Candida albicans accounted for 12.05%.The resistance rate of Staphylococcus aureus to Ampicillin was 100%.The resistance rate of Streptococcus pneumoniae to Levofloxacin and Vancomycin was 0.The resistance rate of Pseudomonas aeruginosa to Ceftriaxone and Aztreonam was 41.67%.The resistance rate of Klebsiella pneumoniae to Penicillins and Ceftriaxone were 54.55%and 45.45%.The drug resistance rate of Escherichia coli to Penicillins and Cephalosporins is as high as 100%.The resistance rate of Candida albicans to Amphotericin B and Fluconazole were 10.00%and 50.00%.Conclusion:There is Gram-negative bacteria infection in most patients with AECOPD and bronchiectasis,with high resistance to Cephalosporins and Penicillins.The resistance is common.It is necessary to use various antibacterials rationally in clinical medication.
作者
张洁
宋娇
卜珊
ZHANG Jie;SONG Jiao;BU Shan(Korla Hospital,Second Division,Xinjiang Production and Construction Corps,Korla 841000,China)
出处
《中国医学创新》
CAS
2021年第28期90-93,共4页
Medical Innovation of China
关键词
慢性阻塞性肺疾病
支气管扩张
病原菌
耐药性
Chronic obstructive pulmonary disease
Bronchiectasis
Pathogen
Drug resistance